France: Sanofi to acquire Provention Bio for US$2.9bn

Global pharmaceutical company, Sanofi, is acquiring Provention Bio, a US-based, publicly traded biopharmaceutical coany focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), in a transaction representing an equity value of approximately US$2.9bn. The deal adds TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D), to…

You must be a HMI Subscriber to view this content.

Subscribe Now »